How to build CAR–M: Carl June protégé and his biotech publish first evidence in Nature Biotechnology
Michael Klichinsky joined the University of Pennsylvania for his PhD at the height of the revolution.
It was 2014, and though the CAR-T therapy that would make Penn professor Carl June famous would not be approved for four years, it had already caused headline-grabbing remissions in a small handful of patients. Klichinsky turned down offers from other elite universities to take a spot between June’s lab and colleague Saar Gill’s lab.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.